AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 191 min read$COLL

Collegium Pharmaceutical Ends Grünenthal Nucynta U.S. License After $17 Million Settlement

Collegium Pharmaceutical settled with Grünenthal for $17M, ending their U.S. license agreement for Nucynta products and resolving pending patent litigation. The deal terminates the 2015 license and 2020 consent agreement, with Collegium gaining certain patents and eliminating future royalties.

Original reporting
tradingview.com
Published Oct 19, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Collegium Pharmaceutical Ends Grünenthal Nucynta U.S. License After $17 Million Settlement — source image
Source · tradingview.com
Decision brief

The 30-second read

$COLLBullishMed
01

Why it matters

The deal eliminates royalty obligations and grants patents to Collegium, likely improving profitability and reducing legal risk.

02

Market read

A material legal settlement for a mid‑cap pharma firm, potentially moving the stock on the news.

03

What to watch

Potential future litigation risk if Grünenthal challenges the patent assignments.

Relevance 6/10Novelty 7/10Timing: post‑filing today

Background

Collegium Pharmaceutical (COLL) announced a settlement with Grünenthal, ending a long‑standing licensing agreement for the opioid Nucynta and paying $17 million.

Company-level read

Ticker impact

$COLLBullishHigh confidence
Context

Collegium Pharmaceutical settled a $17M dispute, terminated its U.S. Nucynta license and received patent assignments.

Expected impact

likely upward pressure as the market prices in reduced royalty costs and stronger patent position

Evidence & confidence

Removal of ongoing royalty payments and acquisition of patents are material to earnings and cash flow.

Market effects

Sector

May affect other generic opioid manufacturers by altering competitive dynamics for Nucynta equivalents.

Regional

Limited to U.S. pharmaceutical market where the license was terminated.

Global

Low; impact confined to Collegium and its niche product line.

Counterpoint

What could challenge this read

The settlement could signal deeper issues with Nucynta's market potential, suggesting a possible downside.

Key entities

  • company
    Collegium Pharmaceutical

    U.S. listed pharmaceutical company (ticker COLL).

  • company
    Grünenthal

    German pharmaceutical firm, original licensor of Nucynta.

Read at source← All news

Related articles

AUG 13
$COLLMedAI 8/10

Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical (COLL) reported Q2 2026 results on an earnings call. Total net product revenue was $199.9M (+6% YoY). Jornay PM revenue rose to $46.1M (+41%) with 30,000+ prescribers. Azstarys revenue was $12.9M post-May acquisition. 2026 guidance: product revenue $825M-$855M; adjusted EBITDA $445M-$470M; adjusted EPS $1.92. Risks cited include authorized-generic pricing impacts.

fool.com8 min
AUG 13
$COLLMed

Why is Collegium Pharmaceutical stock climbing today?

Collegium Pharmaceutical shares rose about 3% in pre-open trading after the company announced a $50 million Accelerated Share Repurchase with Jefferies LLC. Collegium will pay $50 million upfront and receive about 1.56 million shares initially, under a $150 million buyback program authorized in July 2025. The firm reported Q2 net revenues near $199.9 million and reaffirmed 2026 guidance of $805–$825 million.

investing.com4 min
AUG 13
$COLLMed

Collegium Pharmaceutical stock jumps on $50M share buyback

Collegium Pharmaceutical (NASDAQ:COLL) shares rose about 4% premarket after it announced a $50 million accelerated share repurchase with Jefferies LLC. The ASR is part of a $150 million buyback authorized in July 2025, leaving $100 million after completion. Collegium will pay $50 million and initially receive 1,556,420 shares based on a $25.70 Aug. 12, 2026 close; final settlement expected by Q4 2026.

investing.com2 min
AUG 6
$COLLHighAI 9/10

Why is Collegium Pharmaceutical stock tumbling today?

Collegium Pharmaceutical shares fell about 13% in pre-open trading after it reported Q2 2026 results and cut full-year revenue guidance. Net revenues were $199.9M, up 6.3% but below analysts’ ~$201.2M-$201.4M. Adjusted EPS was $1.92 and adjusted EBITDA $113.8M. The pain portfolio faced generic competition, while JORNAY PM rose 41% to $46.1M and AZSTARYS added $12.9M.

investing.com4 min
AUG 6
$COLLHigh

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress – Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Y

SEC EDGAR 8-K7 min